Zeto has revealed the winners of its 2024 Clinical Trial Sponsorship programme. This initiative, announced at the 2023 Society for Neuroscience Convention (11–15 November, Washington, D.C.), invited research teams to submit proposals for clinical trials using the Zeto electroencephalography (EEG) device platform. The programme aims to support advanced clinical research and bring innovative applications closer to real-world implementation.
An expert jury panel composed of professionals from the fields of neurology and neuroscience research carefully reviewed all submissions, and selected the winners based on several factors, including alignment with Zeto’s mission to enhance patient care through innovative EEG applications.
“The winners of the 2024 Clinical Trial Sponsorship programme are conducting groundbreaking research aimed at improving patient care,” said Florian Strelzyk, chief sales officer at Zeto. “These projects align perfectly with Zeto’s mission, and we are proud to support them. We look forward to continuing this sponsorship programme annually.”
The winners of the 2024 Clinical Trial Sponsorship programme are as follows:
- Efficacy of portable EEG technology in pre-hospital triage of large vessel occlusion (LVO) strokes by Liqi Shu and a multidisciplinary team from Brown University and Rhode Island Hospital in Providence, USA: This clinical trial will evaluate the Zeto EEG system’s ability to enhance pre-hospital triage of LVO strokes, aiming to significantly improve diagnostic speed and accuracy. By integrating Zeto’s advanced, portable EEG technology into emergency medical services (EMS) protocols, the study seeks to ensure rapid and appropriate routing of stroke patients to specialised care facilities, thereby optimising treatment times and patient outcomes.
- Gaze-independent visual brain-computer interface (BCI) for use by patients with limited-to-no eye control by Marc M Van Hulle and Arne Van Den Kerchove from KU Leuven in Leuven, Belgium: BCIs have been serving paralysed individuals by decoding their brain activity directly. A popular paradigm requires the patient to gaze at displayed targets, but this is challenging for patients with limited-to-no eye control. The team has developed a gaze-independent paradigm and EEG decoder that copes with this issue, which will be tested on patients using the Zeto EEG headset.
- The far-north remote online Zeto electroencephalography (FROZE) trial by Marcus C Ng from University of Manitoba in Winnipeg, Canada: The FROZE trial will use Zeto EEG in an emergency room in the far north of the Canadian Arctic for use by everyday clinicians backed by remote interpretation from board-certified epileptologists. This trial will determine how effectively the Zeto platform could improve patient care in even the remotest regions of the world.
“We are happy to support the winners of the Clinical Trial Sponsorship programme and to see the advantages of Zeto’s dry EEG headset in action,” said A Mark Mento, director of enterprise sales at Zeto. “Its ease of use, comfort, and ability to bring EEG out of the lab and into the medical research environment, provide significant benefits to researchers in projects such as these.”
Zeto will provide each clinical trial with its US Food and Drug Administration (FDA)-cleared products, including up to two headsets per trial along with electrode supplies for up to 100 patients, accompanied by on-site training and ongoing product support. Trials are set to start before the end of 2024 with an anticipated duration ranging between 6–12 months.
